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Long QT syndrome is characterized by prolongation of the corrected QT (QTc) interval on the surface electrocardiogram and is
associated with precipitation of torsade de pointes (TdP), a polymorphic ventricular tachycardia that may cause sudden death.
Acquired long QT syndrome describes pathologic excessive prolongation of the QT interval, upon exposure to an environmental
stressor, with reversion back to normal following removal of the stressor. The most common environmental stressor in acquired
long QT syndrome is drug therapy. Acquired long QT syndrome is an important issue for clinicians and a signiﬁcant public health
problem concerning the large number of drugs with this adverse eﬀect with a potentially fatal outcome, the large number of
patients exposed to these drugs, and our inability to predict the risk for a given individual. In this paper, we focus on mechanisms
underlying QT prolongation, risk factors for torsades de pointes and describe the short- and long-term treatment of acquired long
QT syndrome.
1.Introduction
Acquired long QT syndrome is a disorder of cardiac repo-
larization most often due to speciﬁc drugs, hypokalemia, or
hypomagnesemiathatmayprecipitatetorsadedepointesand
cause sudden cardiac death. Selzer and Wray ﬁrst reported
QT prolongation and ventricular ﬁbrillation as a response
to quinidine in 1964 [1]. Two years later, Dessertenne [2]
described torsades de pointes, a polymorphic ventricular
tachycardia where QRS complexes twist around an iso-
electric line in a sinusoidal fashion in an elderly woman
with complete atrioventricular block and syncopal attacks
(Figure 1). Torsade de pointes is usually self-limited but
may degenerate into ventricular ﬁbrillation. The incidence
of acquired long QT syndrome is diﬃcult to be estimated.
Although the chances of provoking torsades de pointes by a
noncardiac medication are generally lower than antiarrhyth-
mic medications, a number of noncardiovascular drugs have
beenrecentlywithdrawnfrommarketbecauseofunexpected
sudden cardiac deaths associated with prolongation of QT
interval and torsades de pointes [3]. The frequency of
drug-induced long QT syndrome and our inability to predict
the risk for a given individual, makes long QT syndrome
an important issue for clinicians. This paper focuses on
mechanisms underlying QT prolongation, risk factors for
torsades de pointes and describes the short- and long-term
treatment of acquired long QT syndrome.
2. QT Interval Measurement
QT interval on the surface electrocardiogram describes the
manifestation of ventricular depolarization and repolariza-
tion. It is measured from the beginning of QRS complex
to T wave termination and averaged over 3 to 5 beats in
a single lead. Longest QT intervals are usually measured in
precordial leads and V3 or V4 leads appear more reliable
for assessing QT prolongation [4]. Prominent U waves
should be included in the measurement if they merge into
the T wave. QT interval is inﬂuenced by heart rate. The
RR interval preceding the QT interval should be measured
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Figure 1: Torsades de pointes.
for heart rate correction of the QT interval. The most
commonly used formulae are Fridericia’s cube root formula
(QTc = QT/RR1/3) and Bazett’s square root formula (QTc
= QT/RR1/2). Although there is no consensus on best QTc
method, Bazett’s formula is considered the gold standard,
even though it may overestimate QT prolongation [5].
In general, QT prolongation is considered when the QTc
interval is greater than 440ms, but arrhythmias are most
often associated with values of 500ms or more. QTc interval
is longer in adult women because of a relative shortening of
the QTc interval in men during adolescence [6]. Intervals of
440 to 460 milliseconds in men and 440 to 470 milliseconds
in women are considered borderline [7]. QT intervals may
also vary due to ECG acquisition technique, electrolyte
imbalance, sympathovagal activity, intra- and interobserver
variability, and diurnal variation which can be up to 75–
100ms [8, 9]. It is important to notice that for every
individual there is a diﬀerent relation between the QT
interval and the heart rate, and even though rate-correction
formulae are useful clinically, they may not be accurate
enough, especially when assessing the minor changes of the
QT interval induced by drugs.
3. Mechanisms of Drug-InducedQT
Prolongation
QT interval on the surface electrocardiogram represents the
summation of action potentials in ventricular myocytes.
QT prolongation entails action potential prolongation, that
results from an increase in inward current (e.g., through
sodium or calcium channels) or a decrease in outward
current (e.g., through potassium channels). Myocardial
repolarization is primarily mediated by eﬄux of potassium
ions.Twosubtypesofthedelayedrectiﬁerpotassiumcurrent,
IKr (rapid) and IKs (slow), are predominantly responsible
for repolarization. The two currents have diﬀerent activa-
tion, inactivation, and deactivation characteristics, diﬀerent
sensitivities to blocking drugs [10–12], diﬀerent rate, and
catecholamine sensitivity [13, 14] and were later found to be
the result of expression of diﬀerent genes [15, 16].
The hallmark mechanism of acquired LQTS and TdP
is the blockade of IKr by speciﬁc drugs [17]. IKr current
proteins are encoded by the human ether-a-go-go-related
gene HERG (now termed KCNH2) [18]. Two structural
characteristics account for the unusual susceptibility of
IKr channels to various drugs [19]. First, the presence
of aromatic aminoacids (Tyr652 and Phe656) with side
chains directed towards the large central cavity of the pore
region provides high-aﬃnity binding sites for many of
compounds.Theseaminoacidsarenotpresentinmostother
potassiumchannels,andmutationofKCNH2atthesesitesto
other amino acids reduces binding aﬃnity of several drugs.
Second, while most potassium channels contain two proline
residues in the helix that forms part of the pore that restrict
access to the drug binding site, these two prolines are absent
in KCNH2. Mutation of these residues to the conserved Pro-
Val-Pro results in reduced drug binding [20].
Ikr blockade causes a delay in phase 3 rapid repolar-
ization of the action potential (Figure 2) ,w h i c hi sr e ﬂ e c t e d
by QT prolongation. Prolonged repolarization can cause
earlyafterdepolarizations(EADs)duetoactivationofinward
depolarizing currents (L-type calcium channels or sodium-
calcium exchange current) [21], that appear as depolarizing
oscillations in membrane voltage during phases 2 and 3 of
the action potential (Figure 3). EADs that reach threshold
voltage can cause a ventricular extrasystole preceded by
a long QT interval on the surface ECG. On the other
hand, dispersion of refractoriness due to heterogeneity in
ventricular repolarization can create zones of unidirectional
block. Repetitive extrasystoles, unidirectional block and
zones of slow conduction can lead to reentry and TdP [22].
Torsades de pointes is usually preceded by a short-long-
short ECG sequence (Figure 4)[ 23]. In this case one or
more premature ventricular complexes are followed by a
compensatory pause. The subsequent sinus beat may have
an especially long QT and deformities of T or U waves.
This sinus beat is followed by another premature ventricular
complex that precipitates torsades de pointes [24].
Several other ECG variables besides QT interval have
been proposed to be predictors of TdP. QT dispersion, which
represents the diﬀerence between maximum and minimum
QT intervals, was supposed to be a more direct measure of
spatial heterogeneity of repolarization [25], but proved to be
a disappointing tool, because it is mostly dependent on T
wave morphology [26]. An increasing number of basic and
clinical studies suggest that the interval from the peak to the
end of the electrocardiographic T wave (Tp-e) corresponds
to transmural dispersion of repolarization [27–29]. Pro-
longed QTc interval and Tpeak-Tend was found to correlate
with increased risk for torsades de pointes during acquired
bradyarrhythmias [30] .T h eT p - e / Q Tr a t i os e r v e sa sam o r e
sensitiveindexofarrhythmogenesisasitprovidesanestimate
of dispersion of repolarization relative to total duration of
repolarization. Thereby,iteliminatestheconfoundingeﬀects
of variability of heart rate and interindividual variation of
QT interval [31]. Outlined evidence clearly suggests the
applicability of Tp-e/QT ratio as a potentially important
index of arrhythmogenesis, even though direct validation
of Tp-e interval as a body surface index of transmural
dispersion of repolarization is still lacking [32]. More recent
studies have also provided guidelines for the estimation
of transmural dispersion of repolarization in the case of
more complex T waves, including negative, biphasic, and
triphasic T waves [33]. In such cases, the interval from the
nadir of the ﬁrst component of the T wave to the end of
the T wave was shown to provide an electrocardiographic
approximationoftransmuraldispersionofrepolarization.T-
wave alternans or a change in amplitude or polarity of the
T-wave on alternating beats has been observed in LQTS as aThe Scientiﬁc World Journal 3
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Figure 2: Myocardial action potential. Phase 0 rapid depolarization is mediated by sodium entry into cells. Phase 1 and 3 repolarization
results from potassium eﬄux from cells. Balanced slow calcium entry and potassium exit cause the plateau in phase 2. Potassium reenters
and sodium exits cells during phase 4 recovery.
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Figure 3: Multiple early afterdepolarizations (EADs) from progressively more negative transmembrane potential.
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Figure 4: Short-long-short sequence preceding TdP.
precursor to TdP [34]. T-wave alternans is thought to result
from alternation of the M-cell APD, leading to exaggeration
of transmural dispersion of repolarization during alternate
beats, and thus the potential for development of TdP [35].
Abnormal, giant T-U waves and a slow QRS upstroke
separate TdP initiation in LQTS patients from PVCs in
other heart disease and from other PVCs in LQTS patients.
Abnormal T-U waves support the notion that EADs are the
trigger for TdP in LQTS. If found, they may be an indicator
for imminent risk of TdP [36]. Short-term variability of
QT intervals (as measured from 30 consecutive beats) is
increased in patients with a history of drug-induced long
QT syndrome, suggesting that it could prove to be a
useful noninvasive, easily obtainable parameter aiding the
identiﬁcation of the patient at risk for potentially life-
threatening arrhythmia in the context of drugs with QT
prolonging potential [37].
Although evaluating the eﬀect of a new drug on the QTc
interval is important, conclusions on the potential clinical
risk of TdP associated with its use, based solely on its ability
to prolong the QTc interval, might turn out to be highly
ﬂawed. Tpeak-Tend measurement and Tp-e/QT ratio, giant
T-U waves, slow QRS upstroke, and short-term variability of
QTintervalstendtobeusefulclinicalvariablestopredictrisk
of TdP.4 The Scientiﬁc World Journal
Table 1: Risk factors for drug-induced torsade de pointes.
Female sex
Hypokalemia
Bradycardia
Recent conversion from atrial ﬁbrillation
Congestive heart failure
Left ventricular hypertrophy
High drug concentrations
Rapid rate of intravenous infusion with a QT-prolonging drug
Base-line QT prolongation
Subclinical long QT syndrome
Ion-channel polymorphisms
Severe hypomagnesemia
4. Risk Factors
Multiple clinical risk factors (Table 1) are often present in
an individual case. These factors provide a starting point for
basic research into underlying mechanisms at the genetic,
molecularandcellularlevel.Theoccurrenceofdrug-induced
LQTS is unpredictable in any given individual, but a com-
mon observation is that most patients have at least one iden-
tiﬁable risk factor in addition to drug exposure [38].
A female preponderance has been consistently observed
in multiple studies, with TdP occurring two to three times
more commonly in women than in men [39]. These clinical
observations, coupled with the ﬁnding that the QT shortens
after puberty in males but not female [40], suggest that
sex hormones modulate repolarization. Testosterone, by
increasing IKr, shortens QTc and has been implicated as the
major factor lowering risk of TdP in males [41].
Hypokalemia is another common risk factor in drug-
induced LQTS. Low extracellular potassium paradoxically
reduces IKr by enhanced inactivation [42]o re x a g g e r a t e d
competitive block by sodium [43]. As a result, hypokalemia
prolongs the QT interval. However, the fact that low
extracellular potassium increases IKr blockade by drug, is
of most importance in clinical practice [44]. Correction of
extracellularpotassiumtothehighnormalrangecanshorten
QTintervalandassociatedmorphologicalabnormalities[45,
46].
Pauses, usually after an ectopic beat, precipitate drug-
induced TdP. It is presumed that pause generates the dis-
persion of many electrophysiological properties, notably re-
polarization times, that underlie torsades de pointes [47].
In Holter recordings of patients with drug-induced TdP an
increase in underlying sinus heart rate was reported in the
minutes prior to an event [48]. This ﬁnding suggests that a
pauseinthesettingofheightenedsympatheticactivationand
long QT intervals may be especially arrhythmogenic.
The period shortly after conversion of atrial ﬁbrillation is
characterizedbyincreasedriskoftorsadesdepointes.Studies
using QT/RR plots during atrial ﬁbrillation have shown
rate-independent QT prolongation after conversion to sinus
rhythm [49]. Dofetilide causes only minor QT prolongation
Table 2: Drugs implicated in torsades de pointes.
(1) Antiarrhythmic medications
Class IA (Quinidine, Procainamide, and Disopyramide)
Class III (Dofetilide, Ibutilide, Sotalol, and Amiodarone)
Class IV (Verapamil)
(2) Promotility medications
Cisapride
(3) Antimicrobial medications
Macrolides
Erythromycin
Clarithromycin
Fluoroquinolones
Antiprotozoals
Pentamidine
Antimalarials
Chloroquine
(4) Antipsychotic medications
Phenothiazine neuroleptics
Thioridazine
Chlorpromazine
Butyrophenone neuroleptics
Haloperidol
(5) Miscellaneous medications
Arsenic trioxide
Methadone
during atrial ﬁbrillation, but signiﬁcantly more QT prolon-
gation when given to the same patients after cardioversion
to sinus rhythm [50]. Congestive heart failure [51]a n dl e f t
ventricular hypertrophy are other high-risk situations for
drug-induced torsades de pointes, but further investigation
is needed on molecular and cellular mechanisms.
For the majority of drugs (with the exception of class
IA drugs), risk increases with higher drug concentrations.
ClassIAdrugs(quinidine,disopyramide,andprocainamide)
block outward potassium currents and inward sodium
currents. Sodium current blockade increases as serum levels
increase, but potassium current blockade predominates at
low serum levels. Therefore, TdP frequently occurs at low
or subtherapeutic serum levels [52]. Administration of more
than one drug that prolong repolarization increases the risk
of drug-induced LQTS, but in most cases the mechanism
of increased risk is due to drug-drug interactions altering
metabolism, rather than simple additive eﬀects on IKr.
Cytochrome P450 superfamily of proteins is responsible for
the metabolism of most of the drugs by liver and CYP3A4
is the predominant cytochrome P450. Coadministration of
drugs which are substrates for CYP3A4 and/or IKr blockers
results in further QT prolongation. Drugs that prolong QT
interval and inhibitors of CYP3A4 are shown in Tables
2 and 3. Amiodarone rarely causes torsades de pointes
despite signiﬁcant QT prolongation. Amiodarone blocks
IKr without reverse use dependence and prolongs action
potential duration in a homogenous manner, thus reducing
heterogeneity of refractoriness and making myocardium lessThe Scientiﬁc World Journal 5
Table 3: Inhibitors of CYP3A4.
(1) Antihypertensive medications
Dihydralazine
Diltiazem
Verapamil
(2) Antidepressant and anxiolytic medications
Fluoxetine
Midazolam
(3) Antimicrobial medications
Macrolides
Clarithromycin
Erythromycin
Isoniazid
HIV agents
(4) Endocrine medications
Contraceptives
Ethinylestradiol
Antiprogesterone agent
Estrogen receptor modulators
Tamoxifen
(5) Food and herbal constituents
Bergamottin (grapefruit juice)
Glabridin (licorice)
susceptible to reentry. Additional electrophysiologic eﬀects
that explain its safety include noncompetitive β antagonism
and inward L-calcium channel blockade which may reduce
EADs [53]. The incidence of torsades de pointes at currently
used doses is <1% [54, 55] while with sotalol the incidence
r a n g e sf r o m0 . 8t o3 . 8 %[ 56] and with ibutilide from 3.6 to
8.3% [57, 58]. Verapamil, even though a potent IKr blocker,
rarely causes torsades de pointes [59]. Verapamil reduces
EADs by blocking inward calcium current [60], reduces
transmural dispersion of refractoriness, and shortens QT
interval and the incidence of TdP in a model of acquired
LQTS from combined IKs and IKr block [61].
Subclinical mutations or polymorphisms in congenital
LQTS genes have been described as a risk factor for the drug-
associated form [38]. Patients with subclinical congenital
LQTS may develop TdP after exposure to a QT prolonging
agent [62]. In approximately hundred patients with drug-
induced form of LQTS, congenital LQTS disease genes were
identiﬁed in a percentage of 5–10% and their mutations
classiﬁed them as having the congenital syndrome [63].
Identiﬁcation of these cases emphasizes the increasing recog-
nition of incomplete penetrance. As a result, many patients
with the congenital syndrome have normal baseline ECGs,
but they may be at increased risk for torsades during drug
challenge [64, 65]. First-degree relatives of patients with
drug-induced TdP exhibit greater abnormalities of cardiac
repolarization in comparison with ﬁrst-degree relatives of
patients tolerating QT-prolonging antiarrhythmic therapy
[66].
This variability in the risk of torsade de pointes involves
deﬁningthemolecularmechanismsthatcontroltheduration
of action potential and the QT interval in the normal heart
and in diseases such as the congenital long QT syndrome
or heart failure. The term repolarization reserve has been
proposed as a unifying framework for analysis of risk
factors and their clinical mechanisms [67]. Repolarization
reserve characterizes the capacity of the myocardium to
aﬀect orderly and provide rapid repolarization through nor-
mal mechanisms. In normal hearts, repolarization is accom-
plished by multiple and redundant mechanisms. The pres-
ence of a single risk factor is usually insuﬃcient to elicit a
LQTS phenotype. Multiple subclinical lesions are necessary
in the repolarization process before superimposition of an
IKr-blocking drug can produce marked action potential
prolongation and torsades de pointes.
Genetic modulation of repolarization reserve is thought
to contribute to interindividual diﬀerences in susceptibility
to QT-prolonging drugs. Genetic variations in KCNH2,
KCNE, KCNE2,a n dANKB have been identiﬁed in some
patients with drug-induced torsades de pointes [68, 69]. The
gene in which mutations seem most common is KCNQ1,
whose expression results in IKs [62, 63]. Studies in human
myocytesandincomputationalmodelshaveimplicatedvari-
ability in IKs amplitude as a major contributor to variability
in response to IKr block (i.e., to repolarization reserve)
[70, 71]. IKs amplitude is readily increased by interventions
such as adrenergic stimulation [72] or endothelin [73], but
also by compensatory increase through posttranscriptional
upregulation of underlying units of IKs, likely mediated
by microRNA changes due to sustained reductions of IKr
[74]. The way in which the above-mentioned and other
mechanisms might contribute to IKs regulation during
challenge with an IKr blocker remains a broad area for
investigation, both at the clinical level and at the molecular
level.
Current studies investigate the relationship of common
variants within the human genome termed polymorphisms
and variable risk for torsades de pointes. The most com-
pelling example to date is a single nucleotide polymorphism
(SNP), common in African Americans, that results in
substitution of a tyrosine for serine at position 1103 of the
cardiac sodium channel. The SCN5A variant S1103Y points
to the potential role of ethnicity as a genetic determinant
of repolarization reserve [75]. This is further conﬁrmed
by the unique distribution of certain ion channel variants
across diﬀerent ethnic groups [76–78]. Pharmacogenetics
additionally may determine arrhythmia risk in patients with
acquired LQTS. Genetically determined reduced activity of
cytochrome P450 enzyme CYP3A4 may decrease eﬃcient
metabolism of the QT prolonging drugs thioridazine, ery-
thromycin, and terfenadine [79].
5. Treatment
The cornerstone of the management of acquired LQTS in-
cludes the identiﬁcation and discontinuation of any precip-
itating drug and the aggressive correction of any metabolic
abnormalities, such as hypokalemia or hypomagnesemia.
Most of the episodes of torsade de pointes are short-lived
and terminate spontaneously. However, prolonged episodes6 The Scientiﬁc World Journal
result in hemodynamic compromise and require immediate
cardioversion.
Short-term treatment of the syndrome focuses on pre-
vention of recurrence of torsade de pointes and includes
administration of intravenous magnesium sulfate and tem-
porary transvenous cardiac pacing. Intravenous isopro-
terenol is rarely needed. Important step in the management
of acquired LQTS is withdrawal of oﬀending agents and
correctionofelectrolyteabnormalities[80].Theeﬀectiveness
of lidocaine, phenytoin, or atropine even though reported to
be beneﬁcial is uncertain [81].
Intravenous magnesium is the agent of choice for im-
mediate treatment of torsade de pointes irrespective of the
serum magnesium level. 2g bolus of magnesium sulfate is
followed by intravenous infusion of magnesium at a rate of
2–4mg per minute [82]. The mechanism by which mag-
nesium prevents the recurrences of torsade de points is
unclear. Its action is probably mediated through blockage of
sodium or calcium currents. The only side eﬀect of intra-
venous magnesium is ﬂushing during the bolus injection.
Administration of potassium is an important adjunct to
intravenous magnesium for the short-term prevention of
torsade de pointes, especially if the serum potassium level
is low. Serum potassium should be maintained in the high
normal range. Overdrive transvenous pacing shortens QTc
and is highly eﬀective in preventing recurrences of torsades
de pointes [83], especially when they are precipitated by a
pause or bradycardia. Short-term pacing rates of 90 to 110
beats/minarerecommended.Cardiacpacingpreventspauses
and shortens the QTc interval by enhancing the repolarizing
potassium currents [84]. Isoproterenol is useful if temporary
pacing is unavailable or while preparing for transvenous
catheter insertion [85]. Unlike acquired LQTS, isoproterenol
is contraindicated in patients with congenital LQTS or
ischemic heart disease. Side eﬀects include palpitations and
ﬂushes.
Long-term treatment is rarely required. Conditions that
predispose to electrolyte imbalance must be corrected. In
cases of sick sinus syndrome or atrioventricular block and
bradycardia, permanent pacing may be indicated [86].
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